Immunocore (IMCR) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Competitive landscape and innovation

• Recognizes China's advancements in biotech, especially in immunology and cell therapy, viewing China as both a competitor and opportunity for collaboration.

• Emphasizes the need to continually improve the TCR platform to maintain a competitive edge.

• Incorporates external technological developments into R&D and business strategy.

Artificial intelligence integration

• Uses AI to enhance business operations and R&D efficiency, particularly in target identification and protein-peptide interactions.

• AI accelerates drug discovery and supports regulatory filings and clinical data analysis.

• Expects AI to have a profound long-term impact on the industry.

Regulatory environment and strategy

• FDA interactions are the most impactful regulatory factor, guiding investment and asset development.

• Clear and consistent regulatory guidance is crucial for capital allocation and clinical trial planning.